The Case Western Reserve University Office of Research Administration Division, doing business as University Hospitals of Cleveland, has been awarded a $606,869 federal Project Grant by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to conduct research on "Mechanisms of Androgen Receptor Inverse Agonists in Advanced Prostate Cancer". The 5-year project, beginning in July 2024, will utilize sophisticated molecular biology and computational techniques to map the epigenetic mechanisms driving metastatic castration-resistant prostate cancer (mCRPC), and explore the therapeutic potential of novel androgen receptor (AR) inverse agonists to suppress tumor-driving gene expression programs. The research aims to provide mechanistic understanding of how AR function can be altered using these new drug candidates to overcome treatment resistance in advanced prostate cancer.
Generated 1/28/25, 9:20 AM